Adherence, persistence and switching patterns – once- and twice-daily direct oral anticoagulants (QD versus BID DOACs)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/32840
• EU PAS number:
  EUPAS28224
• Study ID:
  32840
• Official title and acronym:
  Adherence, persistence and switching patterns – once- and twice-daily direct oral anticoagulants (QD versus BID DOACs)
• DARWIN EU® study:
  No
• Study countries:
  Germany

  Italy

  Netherlands
• Study status:
  Finalised

Research institution and networks

Institutions

The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)

Netherlands

Leibniz Institute for Prevention Research and Epidemiology - BIPS

Germany

The PHARMO Institute for Drug Outcomes Research (PHARMO Institute)

Netherlands

Contact details

Irene Bezemer

Study contact

[e-mail]

Ron Herings

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 17/10/2018

Actual: 17/10/2018

Data collection

Planned: 02/01/2019

Actual: 02/01/2019

Date of final study report

Planned: 29/11/2019

Actual: 19/12/2019

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Daiichi Sankyo Europe GmbH

Study protocol

Initial protocol

PHARMO - Protocol QD vs BID DOACs -15jan2019

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable